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Purpose: The COVID-19 pandemic has increased mortality worldwide and those with chronic conditions may 
have been disproportionally affected. However, it is unknown whether the pandemic has changed mortality rates 
for people with epilepsy. We aimed to compare mortality rates in people with epilepsy in Wales during the 
pandemic with pre-pandemic rates. 
Methods: We performed a retrospective study using individual-level linked population-scale anonymised elec-
tronic health records. We identified deaths in people with epilepsy (DPWE), i.e. those with a diagnosis of epi-
lepsy, and deaths associated with epilepsy (DAE), where epilepsy was recorded as a cause of death on death 
certificates. We compared death rates in 2020 with average rates in 2015–2019 using Poisson models to calculate 
death rate ratios. 
Results: There were 188 DAE and 628 DPWE in Wales in 2020 (death rates: 7.7/100,000/year and 25.7/100,000/ 
year). The average rates for DAE and DPWE from 2015 to 2019 were 5.8/100,000/year and 23.8/100,000/year, 
respectively. Death rate ratios (2020 compared to 2015–2019) for DAE were 1.34 (95%CI 1.14–1.57, p<0.001) 
and for DPWE were 1.08 (0.99–1.17, p = 0.09). The death rate ratios for non-COVID deaths (deaths without 
COVID mentioned on death certificates) for DAE were 1.17 (0.99–1.39, p = 0.06) and for DPWE were 0.96 
(0.87–1.05, p = 0.37). 
Conclusions: The significant increase in DAE in Wales during 2020 could be explained by the direct effect of 
COVID-19 infection. Non-COVID-19 deaths have not increased significantly but further work is needed to assess 
the longer-term impact.   
1. Introduction 
Coronavirus disease 2019 (COVID-19) has had a devastating effect 
on people’s health and has resulted in increased mortality worldwide 
[1]. Those with chronic conditions, such as epilepsy, may be dis-
proportionally affected and more susceptible to COVID-19 hospital-
isation and death [2]. 
In addition to the direct effects of COVID-19, the pandemic has 
affected people with epilepsy in several ways. These include the impact 
of COVID-19 on mental health, health services, and healthcare seeking 
behaviour [3,4]. Non-pharmaceutical interventions to decrease virus 
transmission may have increased psychological stress, disrupted sleep, 
and reduced contact with vital social support networks [3]. There has 
been a significant decrease in consultations with health services for 
non-COVID-19 illnesses, including epilepsy, particularly at the onset of 
the pandemic. Specialist epilepsy services in Wales adapted rapidly to 
restrictions imposed during the pandemic, where virtual (telephone and 
video) epilepsy clinics became the norm from March 2020 onwards. This 
very significant restriction on face-to-face contact in specialist and pri-
mary care settings will have altered patient experience [4,5]. Each of 
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these factors can potentially increase seizure frequency and, subse-
quently, the risk of death in people with epilepsy. 
People with epilepsy already have an increased mortality risk when 
compared to the general population [6]. The timely assessment of 
changes in mortality is therefore important to target resources and 
potentially save lives. To our knowledge, there have been no population 
level studies on mortality rates in people with epilepsy during the 
COVID-19 pandemic. We used individual-level, population-scale 
routinely collected, electronic health record (EHR) data to compare 
mortality rates in people with epilepsy during the COVID-19 pandemic 
with background mortality rates. 
2. Method 
We used the Secure Anonymised Information Linkage (SAIL) Data-
bank, which contains anonymised individual-level, population-scale 
routinely collected EHR data sources from multiple different sources. 
These include hospital admission and demographic data for the com-
plete Welsh population (3.1 million) and primary care records for 80% 
of the population [7,8]. 
Our study population consisted of all individuals living in Wales 
registered with a Welsh General Practice (GP) contributing data to SAIL 
during 1/1/2015–31/12/2020. We used primary care, death certificate 
and demographic data and analysed epilepsy-related deaths in two 
ways: 
Deaths associated with epilepsy (DAE) had an International Classi-
fication of Diseases version 10 (ICD10) code for epilepsy in any of the ten 
cause of death positions on death certificate data (see Supplementary 
information S1 for codes) [9]; this included people who did not neces-
sarily receive a diagnosis of epilepsy before death. 
Deaths in people with epilepsy (DPWE) were deaths from all causes 
in individuals with a diagnosis of epilepsy before death. Using a previ-
ously validated method, we defined a person as having epilepsy if their 
GP record contained Read codes for an epilepsy diagnosis (S2) and a 
prescription of an anti-seizure medication (S3) on two separate occa-
sions within 6 months [10]. These include people of all ages with 
epilepsy. 
We calculated monthly and annual death rates by dividing DAE and 
DPWE by the total study population on January 1st of the relevant study 
year. COVID-19 deaths were defined as deaths with the ICD-10 codes 
U07.1 and U07.2 recorded in any position on death certificates. The first 
COVID-19 death in Wales was recorded in March 2020. 
We used Poisson regression models to calculate death rate ratios for 
each group in: (i) 2020 compared with 2015–2019 and (ii) each month 
in 2020 compared the same month in 2015–2019. Data from each 
individual year (2015–2020) and month were used in the model with the 
study population as an offset. R version 3.5.2 was used for analyses. 
This study was approved by the SAIL independent Information 
Governance Review Panel (IGRP) (ref 0696). The Research Ethics Ser-
vice has confirmed that SAIL projects using anonymised, routinely 
collected data do not require research ethics committee approval. 
3. Results 
We analysed 14.9 million patient-years of data. The mean number of 
people with epilepsy was 24,560 and the mean population was 
2481,516 for each study year (2015–2020) (mean epilepsy preva-
lence=0.99%). During the study period, there were 904 deaths associ-
ated with epilepsy (DAE) and 3595 deaths in people with epilepsy 
(DPWE). See Table 1 for deaths per year and Fig. 1 and Supplementary 
Table 4 for deaths per month. 
DAE in 2020 increased significantly when compared to DAE in 
2015–2019 [death rate ratio=1.34 (95% CI 1.14–1.57,p<0.001)];12% 
were COVID-related. Non-COVID DAE in 2020 had a smaller, non- 
statistically significant increase [death rate ratio=1.17 (0.99–1.39,p =
0.06)]. 
There was a non-significant increase in DPWE in 2020 when 
compared to 2015–2019, [death rate ratio=1.08 (0.99–1.17,p =
0.09)];13% were COVID-related. Non-COVID DPWE did not change 
significantly when compared to DPWE in 2015–2019 (death rate 
ratio=0.96 (0.87–1.05, p = 0.37)]. 
4. Discussion 
There was a significant increase in deaths associated with epilepsy 
(DAE) in Wales in 2020 compared with DAE 2015–2019. There was a 
smaller, non-statistically significant, increase in deaths in people with 
epilepsy (DPWE). 
Most of this excess mortality can be explained by deaths directly 
caused by COVID-19 given that non-COVID-19 DAE and DPWE have not 
increased. This means that the indirect effects of the pandemic, such as 
disruptions to healthcare, are unlikely to have increased deaths in both 
groups. It may be that changes during the pandemic such as more access 
to remote consultations, reduced rates of other infections, and more 
family/carers available at home have not unduly disadvantaged people 
with epilepsy. 
The trends in DAE and DPWE broadly reflect the pattern for all 
deaths in Wales. Monthly patterns in DAE and DPWE (Fig. 1, S4) also 
reflect monthly patterns in all-cause mortality with a significant peak 
occurring in April 2020 during the peak of the “first wave” of COVID-19 
Table 1 
Deaths associated with epilepsy (DAE) and in people with epilepsy (DPWE) in 2020 and preceding years. All deaths and non-COVID deaths are shown in separate rows. 
Death rates are per 100,000 per year. Death rate ratios are the ratio of 2020 death rates to 2015–2019 rates with confidence intervals from Poisson regression models. 
Death rate ratios that are significantly different to background rates are shown in bold. Non-COVID-19 deaths are deaths without COVID-19 mentioned on the death 
certificate. § DAE and DPWE populations are the total number of people registered with a Welsh GP that contribute data to SAIL (covering approx. 80% of the Welsh 
population). The population for all Welsh deaths is the total Welsh population. Populations are estimated from figures taken on 1st January.   
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in Wales. There were lower rates in DAE and DPWE during summer 
months when COVID-19 rates were low. 
Background rates of DPWE are around four times higher than DAE 
(23.8/100,000/year compared with 5.8/100,000/year). DAE are more 
likely to be directly related to epilepsy prompting the recording of the 
diagnosis on the death certificate, for example, deaths due to sudden 
death in epilepsy (SUDEP), status epilepticus, or injuries directly related 
to seizures. DPWE likely include more deaths not directly related to 
epilepsy. 
We have been able to rapidly analyse contemporaneous individual- 
level population-scale healthcare data. We have used a validated 
method of ascertaining people with an established diagnosis of epilepsy to 
study deaths in people with epilepsy as well as for people with deaths 
associated with epilepsy. We have also completed a detailed comparison 
with background mortality rates in 2015–2019. Our analysis will allow 
for further, more detailed, assessment of the impact of the second UK 
wave of Covid-19 infections on people living with epilepsy and the 
longer-term impact on mortality. 
Fig. 1. All and non-COVID death rates per month in 2020 for: (A) deaths associated with epilepsy (DAE), (B) deaths in people with epilepsy (DPWE) and (C) all 
deaths in Wales. Note there are different scales on the vertical axis. The grey shading indicates the range of the corresponding monthly death rates for the years 
2015–2019. The dotted black line represents mean death rates for 2015–2019. Orange points and lines are total deaths, blue points and lines are non-COVID-19 
deaths (deaths without COVID-19 on the death certificate). *Asterisks represent death rates that are significantly different to the 2015–2019 background rate. A 
range of values (blue error bars) has been displayed for some non-COVID-19 death rates as exact values cannot be displayed due to small numbers of COVID-19 
deaths (<5). 
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Epilepsy is a heterogeneous disorder with many different causes, 
affecting people of all ages, with a high proportion of comorbidities. We 
have not accounted for these differences. It may be that particular 
subgroups, for example older people with epilepsy or people with epi-
lepsy and comorbid intellectual disability or dementia, have had 
differing mortality rates when compared with people with epilepsy as a 
whole, particularly given the strong association between age and 
COVID-19 mortality. Our method for identifying people with epilepsy 
would have included a proportion who have been seizure free at time of 
death, and this may have biased results. People living in areas of 
increased socioeconomic deprivation have increased epilepsy preva-
lence and have been disproportionally affected by COVID—we have not 
accounted for this in our analysis [11]. We also did not account for the 
position that epilepsy was recorded on the death certificate, which may 
influence the strength of association of epilepsy with the death. 
There is likely a delay in epilepsy diagnoses recording in primary 
care and we were not able to record new diagnosis of epilepsy made 
from October 2020. This means that DPWE may be slightly higher than 
recorded here although these factors will not have affected our figures 
for DAE. Sudden and unexpected death in epilepsy (SUDEP) is a rare but 
devastating cause of death in people with epilepsy. We have not spe-
cifically looked at SUDEP as it is poorly coded in routinely collected data 
[12]. 
Conclusion 
In this population-scale study of epilepsy mortality we have found 
that deaths associated with epilepsy increased significantly in 2020 
when compared with rates from 2015 to 2019. This is largely explained 
by COVID-19 related deaths as non-COVID-19 deaths associated with 
epilepsy and non-COVID-19 deaths in people with epilepsy have not 
increased significantly. Further research is necessary, such as sub-group 
analysis by age, epilepsy severity, and co-morbidity, to assess the longer- 
term impact of COVID on epilepsy, especially in vulnerable groups. 
Declaration of Competing Interest 
None of the authors have any conflicts of interest to disclose. 
Acknowledgements 
This work was supported by Health Data Research UK, which re-
ceives its funding from HDR UK Ltd (HDR-9006) funded by the UK 
Medical Research Council, Engineering and Physical Sciences 
Research Council, Economic and Social Research Council, Department 
of Health and Social Care (England), Chief Scientist Office of the Scottish 
Government Health and Social Care Directorates, Health and Social Care 
Research and Development Division (Welsh Government), Public Health 
Agency (Northern Ireland), British Heart Foundation (BHF) and the 
Wellcome Trust. JH was supported by Health and Care research Wales 
[Project: SCF-18-1504]. AA, JH and RL were supported by the con-cov 
grant funded by the Medical Research Council (Grant No. MR/ 
V028367/1), ADR Wales programme of work funded by the ADR UK 
(Grant ES/S007393/1) and the Wales COVID-19 Evidence Centre, fun-
ded by Health and Care Research Wales. 
This work was supported by staff funded as part of the Brain Repair 
and Intracranial Neurotherapeutics (BRAIN) Unit and the Wales Gene 
Park, infrastructure support groups funded by Welsh Government 
through Health and Care Research Wales. 
This study makes use of anonymised data held in the Secure Ano-
nymised Information Linkage (SAIL) Databank. We would like to 
acknowledge all the data providers who make anonymised data avail-
able for research. Approval for the use of data in this study, within the 
SAIL Databank, was granted by an independent information governance 
review panel (project 0696). 
The work described here is consistent with the Journal’s guidelines 
for ethical publication. 
Supplementary materials 
Supplementary material associated with this article can be found, in 
the online version, at doi:10.1016/j.seizure.2021.11.017. 
References 
[1] Giattino C., Ritchie H., Roser M., et al.Excess mortality during the Coronavirus 
pandemic (COVID-19) - statistics and research - our world in data. 2021. https://ou 
rworldindata.org/excess-mortality-covid. 
[2] Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm 
(QCOVID) for risk of hospital admission and mortality from coronavirus 19 in 
adults: national derivation and validation cohort study. BMJ 2020;371. https:// 
doi.org/10.1136/bmj.m3731. 
[3] Thorpe J, Ashby S, Hallab A, et al. Evaluating risk to people with epilepsy during 
the COVID-19 pandemic: preliminary findings from the COV-E study. Epilepsy 
Behav 2021;115. https://doi.org/10.1016/j.yebeh.2020.107658. 
[4] Leung WCY, Lau EHY, Kwan P, et al. Impact of COVID-19 on seizure-related 
emergency attendances and hospital admissions — a territory-wide observational 
study. Epilepsy Behav 2020;115. https://doi.org/10.1016/j.yebeh.2020.107497. 
[5] Thornton J. Covid-19: A&E visits in England fall by 25% in week after lockdown. 
BMJ 2020;369:m1401. 
[6] Morrish P, Duncan S, Cock H. Epilepsy deaths: learning from health service 
delivery and trying to reduce risk. Epilepsy Behav 2020;103:106473. 
[7 Jones KH, Ford DV, Thompson S, et al. A profile of the SAIL databank on the UK 
secure research platform. Int J Popul Data Sci 2019;4. https://doi.org/10.23889/ 
ijpds.v4i2.1134. 
[8] Ford DV, Jones KH, Verplancke JP, et al. The SAIL Databank: building a national 
architecture for e-health research and evaluation. BMC Health Serv Res 2009;4: 
157. 
[9] Public Health England. Deaths associated with neurological conditions in England 
2001 to 2014: data analysis report. 2018. 
[10] Fonferko-Shadrach B, Lacey AS, White CP, et al. Validating epilepsy diagnoses in 
routinely collected data. Seizure 2017;52:195–8. https://doi.org/10.1016/j. 
seizure.2017.10.008. 
[11] Pickrell WO, Lacey AS, Bodger OG, et al. Epilepsy and deprivation, a data linkage 
study. Epilepsia 2015;56(4):585–91. https://doi.org/10.1111/epi.12942. Epub 
2015 Mar 2. 
[12] Pickrell WO, Kerr MP. SUDEP and mortality in epilepsy: the role of routinely 
collected healthcare data, registries, and health inequalities. Epilepsy Behav 2020; 
103(Pt B):106453. 
H. Daniels et al.                                                                                                                                                                                                                                 
